Leuven, BELGIUM, Boston, MA, US – March 25, 2022 – 09.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, published its annual report for the financial year 2021. The annual report for the year ended 2021 is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-687 is a highly selective pan-RGD integrin antagonist that is being developed as a potential first line therapy for DME patients as well as wet AMD and potentially ME-RVO. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com. For more information, please contact: Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.com Michaël DillenChief Business OfficerTel: +32 479 783 583michael.dillen@oxurion.com EUMEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel: +44 203 928 6900oxurion@medistrava.com USWestwicke, an ICR CompanyChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com